Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Net Income towards Common Stockholders (2016 - 2025)

Lisata Therapeutics filings provide 13 years of Net Income towards Common Stockholders readings, the most recent being -$3.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 35.92% year-over-year to -$3.0 million, compared with a TTM value of -$16.6 million through Dec 2025, up 17.01%, and an annual FY2025 reading of -$16.6 million, up 17.01% over the prior year.
  • Net Income towards Common Stockholders hit -$3.0 million in Q4 2025 for Lisata Therapeutics, up from -$4.2 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$3.0 million in Q4 2025, with the low at -$6.2 million in Q1 2023.
  • Median Net Income towards Common Stockholders over the past 3 years was -$4.8 million (2024), compared with a mean of -$4.8 million.
  • The sharpest move saw Net Income towards Common Stockholders dropped 25.25% in 2024, then surged 35.92% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$5.4 million in 2023, then increased by 14.07% to -$4.6 million in 2024, then skyrocketed by 35.92% to -$3.0 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$3.0 million, -$4.2 million, and -$4.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.